Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Single-Dose Study to Evaluate the Response and Pharmacokinetics/Pharmacodynamics of Different Doses of CINRYZE® [C1 Inhibitor (Human)] For Treatment of Acute Angioedema Attacks in Children Less Than 12 Years of Age With Hereditary Angioedema

NCT01095510 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01095510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01095510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Single-Dose Study to Evaluate the Response and Pharmacokinetics/Pharmacodynamics of Different Doses of CINRYZE® [C1 Inhibitor (Human)] For Treatment of Acute Angioedema Attacks in Children Less Than 12 Years of Age With Hereditary Angioedema
Lead sponsor
Shire
Phase
Phase 2
Overall status
Completed
Start date
June 2, 2010
Completion date
April 17, 2012
Enrollment
9 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema (hae)